Insights on the Ephrin Type B Receptor Market to 2027 | Industry Statistics, Emerging Demands, Forecast to 2027

The global ephrin type B receptor market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Eph receptors are a group of receptors that activates in response to binding with Eph receptor-interacting proteins (Ephrins). These receptors belong to the largest known subfamily of receptor tyrosine kinases (RTKs). The major factor contributing to the growth of the market is the increasing prevalence of cancer across the globe. According to the National Cancer Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be diagnosed in the US with a mortality rate of 606,520 people in 2020. In men, prostate, lung, and colorectal cancers will account for an estimated 43% of all cancers diagnosed while for women, the three most common cancers include breast, lung, and colorectal which will account for an estimated 50% of all new cancer diagnoses in women in 2020.

To Request a Sample of our Report on Ephrin Type B Receptor Market: https://www.omrglobal.com/request-sample/ephrin-type-b-receptor-market

Furthermore, there were 18.1 million new cases and 9.5 million cancer-related mortalities globally in 2018 which is anticipated to rise to 29.5 million and the number of cancer-related mortalities to 16.4 million by 2040. Hence, the rising prevalence of the disease is driving the demand for ephrin type B receptor for the treatment which in turn is driving the growth of the market. Cutaneous squamous cell carcinoma (CSCC) is the most commong type of metastatic skin cancer. The activation of ephrin type B receptor 2 signaling can promote the metastasis, invasion, and angiogenesis of CSCC cells. Hence, ephrin type B receptor 2 may act as a therapeutic target for CSCC. Some major players operating in the market include Eisai Co., Ltd., Kadmon Corp., and VasGene Therapeutics Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.

Market Coverage

• The market number available for - 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Eisai Co Ltd., Kadmon Corp., and VasGene Therapeutics Inc., among others.

(Get 15% Discount on Buying this Report)

A full Report of Ephrin Type B Receptor Market is Available @ https://www.omrglobal.com/industry-reports/ephrin-type-b-receptor-market

Global Ephrin Type B Receptor Market Report by Segment

By Type

• VDAU-11

• Vas-01

• Tesevatinib Tosylate

• Others

By Application

• Solid Tumor

• Bile Duct Cancer

• Colorectal Cancer

• Melanoma

• Others

Global Ephrin Type B Receptor Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.